Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

105

Authors_(Last_Name)

Razeghian E., Margiana R., Chupradit S., Bokov D.O., Abdelbasset W.K., Marofi F., Shariatzadeh S., Tosan F., Jarahian M.

Author S Id

57223052224;56685900600;57211329338;56845561300;57208873763;57199650994;57225946579;57216155951;16241593900;

Title

Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy

Year

2021

Source Title

Frontiers in Medicine

Volume

Issue

Art No

721174

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114747651&doi=10.3389%2ffmed.2021.721174&partnerID=40&md5=eb488365f37edbafb0ec0a51d29dbfc9

Affiliations

Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran; Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Cipto Mangunkusumo Hospital, The National Referral Hospital, Central Jakarta, Indonesia; Master's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation; Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation; Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt; Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran; Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran; Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, Germany

Authors With Affiliations

Razeghian, E., Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran; Margiana, R., Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Cipto Mangunkusumo Hospital, The National Referral Hospital, Central Jakarta, Indonesia, Master's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Chupradit, S., Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Bokov, D.O., Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation, Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation; Abdelbasset, W.K., Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia, Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt; Marofi, F., Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran; Shariatzadeh, S., Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Tosan, F., Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran; Jarahian, M., Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, Germany

Abstract

Pro-inflammatory cytokines can effectively be used for tumor immunotherapy, affecting every step of the tumor immunity cycle. Thereby, they can restore antigen priming, improve the effector immune cell frequencies in the tumor microenvironment (TME), and eventually strengthen their cytolytic function. A renewed interest in the anticancer competencies of cytokines has resulted in a substantial promotion in the number of trials to address the safety and efficacy of cytokine-based therapeutic options. However, low response rate along with the high toxicity associated with high-dose cytokine for reaching desired therapeutic outcomes negatively affect their clinical utility. Recently, mesenchymal stem/stromal cells (MSCs) due to their pronounced tropism to tumors and also lower immunogenicity have become a promising vehicle for cytokine delivery for human malignancies. MSC-based delivery of the cytokine can lead to the more effective immune cell-induced antitumor response and provide sustained release of target cytokines, as widely evidenced in a myriad of xenograft models. In the current review, we offer a summary of the novel trends in cytokine immunotherapy using MSCs as a potent and encouraging carrier for antitumor cytokines, focusing on the last two decades' animal reports. ? Copyright ? 2021 Razeghian, Margiana, Chupradit, Bokov, Abdelbasset, Marofi, Shariatzadeh, Tosan and Jarahian.

Author Keywords

cytokine; cytokine delivery; gene therapy; mesenchymal stem/stromal cells; tumor-immunotherapy

Index Keywords

Publisher

Frontiers Media S.A.

Issn

2296858X

Isbn

Pubmed Id

Document Type

Review

Sjr Best Quartile

Sjr

1388

Sjr Rank

2608